A study on the safety and efficacy of reveglucosidase alfa in patients with late-onset Pompe disease

BACKGROUND: Late-onset Pompe disease is a rare genetic neuromuscular disorder caused by lysosomal acid alpha-glucosidase (GAA) deficiency that ultimately results in mobility loss and respiratory failure. Current enzyme replacement therapy with recombinant human (rh)GAA has demonstrated efficacy in s...

Descripción completa

Detalles Bibliográficos
Autores principales: Byrne, Barry J., Geberhiwot, Tarekegn, Barshop, Bruce A., Barohn, Richard, Hughes, Derralynn, Bratkovic, Drago, Desnuelle, Claude, Laforet, Pascal, Mengel, Eugen, Roberts, Mark, Haroldsen, Peter, Reilley, Kristin, Jayaram, Kala, Yang, Ke, Walsh, Liron
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5571484/
https://www.ncbi.nlm.nih.gov/pubmed/28838325
http://dx.doi.org/10.1186/s13023-017-0693-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5571484/
https://www.ncbi.nlm.nih.gov/pubmed/28838325
http://dx.doi.org/10.1186/s13023-017-0693-2

Ejemplares similares